In fact, the anti-parasitic nitazoxanide used to treat CRC patients, efficiently inhibits the Wnt signaling pathway by increasing the stability of the PADI2 protein and enhancing the citrullination of β-catenin, which inhibits the Wnt pathway and thereby decrease the cellular proliferation of colon cancer cells. The gene discussed is PADI2; the disease is malignant colon neoplasm.